Repaglinide versus nateglinide monotherapy: A randomized, multicenter study

Diabetes Care

Volumn 27, Issue 6, 2004, Pages 1265-1270

  Rosenstock, Julio ^a   Hassman, David R ^b   Madder, Robert D ^c   Brazinsky, Shari A ^d   Farrell, James ^e   Khutoryansky, Naum ^f   Hale, Paula M ^f  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b Comprehensive Clinical Research ^*  (United States)

^c Tri State Medical Group   (United States)

^d Inst of Hlth Care Assessment Inc   (United States)

^e Midwest Pharmaceutical Research   (United States)

^f NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; METFORMIN; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TEST MEAL; WEIGHT GAIN;

BIOLOGICAL MARKERS; BODY MASS INDEX; CARBAMATES; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; EXERCISE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHENYLALANINE; PIPERIDINES; TIME FACTORS;

EID: 2542479374     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.6.1265     Document Type: Article

References (17)

1. Novo Nordisk Pharmaceuticals: Repaglinide product labeling, 2003
2. Novartis Pharmaceuticals: Nateglinide product labeling, 2003
3. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J: Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium channels and cytosolic calcium levels in bTC3 cells and rat pancreatic β-cells. Diabetologia 38: 1025-1032, 1995
4. Chachin M, Yamada M, Fujita A, Matsuoka T, Matsushita K, Kurachi Y: Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic β-cell-type K(ATP) channels. J Pharmacol Exp Ther 304:1025-1032, 2003
5. Hansen AM, Christensen IT, Hansen IB, Carr RD, Ashcroft FM, Wahl P: Differential actions of nateglinide and repaglinide on the human β-cell sulphonylurea receptor. Diabetes 51:2789-2795, 2002
6. Marbury T, Huang WC, Strange P, Lebovitz H: Repaglinide versus glyburide: a 1-year comparison trial. Diabetes Res Clin Pract 43:155-166, 1999
7. Madsbad S, Kilhovd B, Lagert I, Mustajoki P, Dejgaard A: Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med 18:395-401, 2001
8. Carroll MF, Ahmad I, Riboni K, Burge MR, Schade DS: Control of postprandial hyperglycemia: optimal use of short-actingsecretagogues. Diabetes Care 25:2147-2152, 2002
9. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I: Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 24:11-15, 2001
10. Van Gaal LF, Van Acker KL, de Leeuw IH: Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. Diabetes Res Clin Pract 53:141-148, 2001
11. Hanefield M, Bouter KP, Dickinson S, Guitard C: Rapid and short-acting meal-time insulin secretion with nateglinide controls both prandial and mean glycaemia. Diabetes Care 23:202-207, 2000
12. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S: Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660-1665, 2000
13. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes. J Am Med Assoc 287:360-372, 2002
14. Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM: Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 26:2063-2068, 2003
15. Khutoryansky NM, Huang WC: Imputation techniques using SAS software for incomplete data in diabetes clinical trials. In Pharmaceutical Industry SAS Users Group Conference Proceedings, Boston, MA, 20-23 May 2001. p. 334-337
16. Rosenstock J, Gatlin MR, Shen SG, Foley JE: Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 25:1529-1533, 2002
17. Hu S, Wang S, Fanelli B, Bell PA, Dunning RE, Geisse S, Schmitz R, Boettcher BR: Pancreatic β-cell channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 293:444-452, 2000